---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000982"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-07-29T20:31:21+00:00"
generated_at: "2026-07-29T20:32:19.613658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Splash Beverage expands CannEpil license to veterinary applications, targets FDA approval

## Summary
- Expanded exclusive global license for CannEpil to include veterinary therapeutics; royalty 10% of vet net revenue, 15% human.
- Initial focus on canine oncology and chronic pain; global veterinary pain market ~$2.6B in 2024, projected $3.8B by 2030.
- Company finalizing joint venture with established cannabinoid pharmaceutical firm to lead veterinary development program.
- CannEpil is a pharmaceutical-grade CBD/THC oral solution with EU-GMP certification and IND for human program.
- Will pursue FDA Center for Veterinary Medicine INAD and Conditional Approval pathways; no assurance of approval.

## SEC filing metadata
- accession: 0001731122-26-000982
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-07-29T20:31:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000982/0001731122-26-000982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000982/e7811_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000982
- JSON: https://secwatch.observer/filing/0001731122-26-000982.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.